Lexaria Bioscience/$LEXX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lexaria Bioscience
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
Ticker
$LEXX
Sector
Primary listing
Employees
7
Headquarters
Kelowna, Canada
Website
LEXX Metrics
BasicAdvanced
$15m
-
-$0.46
0.33
-
Price and volume
Market cap
$15m
Beta
0.33
52-week high
$1.55
52-week low
$0.46
Average daily volume
110k
Financial strength
Current ratio
26.88
Quick ratio
24.742
Long term debt to equity
1.004
Total debt to equity
1.52
Profitability
EBITDA (TTM)
-9.129
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-2,589.65%
Operating margin (TTM)
-2,504.67%
Effective tax rate (TTM)
-0.05%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-75.97%
Return on equity (TTM)
-147.07%
Valuation
Price to revenue (TTM)
33.479
Price to book
2.22
Price to tangible book (TTM)
2.33
Price to free cash flow (TTM)
-1.301
Free cash flow yield (TTM)
-76.86%
Free cash flow per share (TTM)
-0.453
Growth
Revenue change (TTM)
-30.03%
Earnings per share change (TTM)
-22.65%
3-year revenue growth (CAGR)
3.84%
10-year revenue growth (CAGR)
25.57%
3-year earnings per share growth (CAGR)
-26.77%
10-year earnings per share growth (CAGR)
-8.72%
LEXX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs